对糖尿病患者心血管风险患者的他类药物处方实践的回顾性审计
Muhammad Adnan Khaliq1, Sabih Nofal2, Samia Israr3
1Internal Medicine, Services Hospital, Lahore, PAK.
Cureus
|September 16, 2025
概括
糖尿病患者通常不接受指导方针推的他类药物治疗,导致使用不足和低于最佳剂量,特别是在女性和年轻人中. 改善坚持是预防心血管疾病的关键,在这个高风险人群中.
科学领域:
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
- 公共卫生 公共卫生
背景情况:
- 糖尿病患者面临心血管疾病 (CVD) 的风险增加.
- 准则建议对大多数40岁以上或已确诊的动脉样硬化心血管疾病 (ASCVD) 的糖尿病患者进行他类药物治疗.
研究的目的:
- 对糖尿病患者和心血管风险患者的基于指南的他类药物处方的遵守进行审计.
- 为了确定他类药物处方强度和资格方面的差距.
主要方法:
- 对131名糖尿病患者的医疗记录进行了回顾性审计.
- 收集的数据包括人口统计,糖尿病持续时间,并发症,脂质概况,心血管疾病史和他类药物处方细节.
主要成果:
- 83.2%的糖尿病患者有资格接受他类药物治疗; 77.1%接受了他类药物治疗,但22.9%仍未接受治疗.
- 高强度他类药物仅在33.3%的合格病例中被处方.
- 在女性 (69.2%) 和男性 (83.8%) 和年轻患者中,静止剂的使用率较低.
结论:
- 在糖尿病患者中观察到显著的他类药物使用不足和低于最佳剂量的情况.
- 坚持的差距值得注意,特别是对于女性和年轻人来说.
- 需要加强临床坚持策略,以改善心血管疾病的结果.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.3K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
Atherosclerosis III: Management
322
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
322
Coronary Artery Disease V: Interprofessional Care
215
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
215
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
197
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
197
Coronary Artery Disease IV: Preventive Measures
590
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
590
Pharmacovigilance
1.6K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.6K
